PACM-07 PHARMACOLOGIC BLOOD-BRAIN BARRIER MODULATION WITH REGADENOSON IMPROVES DRUG DELIVERY IN BRAIN METASTASIS
Clicks: 1
ID: 324434
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #84 of 103 articles by views in Neuro-Oncology Advances
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Brain metastases are a frequent and clinically devastating complication of metastatic breast cancer, in part because many systemic therapies fail to achieve therapeutic concentrations in the central nervous system (CNS). Regadenoson (Reg), an FDA-approved A2A adenosine receptor agonist used for cardiac stress testing, has been proposed as a pharmacologic modulator of blood-brain barrier (BBB) permeability. Methods We evaluated whether Reg enhances CNS delivery of doxorubicin (Dox) and a 70-kDa fluorescent dextran tracer in non-tumor-bearing brain and in models of triple-negative breast cancer (TNBC) brain metastasis. In non-tumor-bearing mice, Reg was administered with Dox to define dose and timing conditions that maximize brain accumulation. Brain delivery was quantified by tissue-based analysis. Macromolecular delivery was assessed using whole-brain imaging of 70-kDa dextran. Reg was then tested in TNBC brain metastasis models, where intralesional Dox accumulation and tumor killing were measured. Results Co-administration of Reg with Dox produced the greatest effect, whereas longer lag times reduced efficacy. The optimal Reg dose was 0.005 mg/kg, equivalent to the FDA-approved cardiac stress test dose. At this dose, Reg increased brain Dox accumulation 6-fold in non-tumor-bearing mice versus Dox alone (P < 0.001). Reg also increased the distribution of a 70-kDa dextran by 4.5-fold (P < 0.01). In TNBC brain metastasis models, Dox was not detectable in lesions after Dox alone but became detectable following co-administration with Reg. This was accompanied by a 12- to 16-fold increase in the expression of pro-apoptotic markers γ-H2AX and BAX (P < 0.02) in cancer cells. Conclusions Reg transiently enhances CNS drug delivery across both the non-tumor-bearing BBB and the BBB/blood-tumor barrier in TNBC brain metastases, supporting further evaluation as a pharmacologic adjunct to improve therapy for breast cancer brain metastasis.
| Reference Key |
openalex_W7201869562
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yi Shi, Alyssa Weinstein, Swathi Talluri, Harsh Oza, Inês Godet, David Kamson, stuart grossman, Saraswati Sukumar, Daniele Gilkes |
| Journal | Neuro-Oncology Advances |
| Year | 2026 |
| DOI |
10.1093/noajnl/vdag161.072
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.